Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jun 7, 2020; 26(21): 2821-2830
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2821
Table 1 Clinical summary of the patients with infantile cholestasis
Overall (n = 155)BA (n = 110)Non-BA (n = 45)P value
Demographics
Age (d)57.6 ± 34.459.7 ± 30.352.4 ± 42.80.303
Gender (M:F)61:9441:6920:250.470
Laboratory results
APRI1.32 ± 1.611.47 ± 1.660.95 ± 1.420.069
Imaging findings
PT (mm)4.9 ± 1.85.7 ± 1.42.9 ± 0.9< 0.001
SR1.02 ± 0.201.07 ± 0.190.91 ± 0.17< 0.001
METAVIR grades (Patients’ number)
F0/F1/F2/F3/F432/10/66/37/101/4/59/37/931/6/7/0/1< 0.001
Table 2 Comparison and correlation analyses for fibrosis grading
Age (d)APRIPT (mm)SR
Hepatic fibrosis group comparison
F0 (n = 32)40.8 ± 34.81.12 ± 1.633.1 ± 1.10.89 ± 0.15
F1 (n = 10)60.6 ± 44.00.46 ± 0.383.3 ± 1.30.94 ± 0.20
F2 (n = 66)52.3 ± 31.01.14 ± 1.235.2 ± 1.41.01 ± 0.17
F3 (n = 37)71.9 ± 28.62.00 ± 2.275.9 ± 1.61.12 ± 0.20
F4 (n = 10)89.7 ± 26.61.52 ± 0.555.7 ± 1.61.21 ± 0.17
P value< 0.0010.026< 0.001< 0.001
Correlation analysis
Overall correlation
τ0.3130.3260.4480.361
P value< 0.001< 0.001< 0.001< 0.001
Partial correlation with adjusting age
τ0.0710.5180.340
P value0.405< 0.001< 0.001
Table 3 Diagnostic performance of the parameters
VariableCutoff valueSensitivity (%)Specificity (%)AUC95%CIP value
Clinically significant fibrosis (F2-F4)
APRI0.4484.159.50.7120.634-0.7820.001
PT4.2 mm81.485.70.8990.840-0.941< 0.001
SR0.8585.054.80.7410.664-0.808< 0.001
Advanced fibrosis (F3-F4)
APRI0.7878.763.00.7240.647-0.793< 0.001
PT5.3 mm66.071.30.7340.657-0.801< 0.001
SR1.161.778.70.7420.666-0.809< 0.001
Cirrhosis (F4)
APRI1.2490.070.30.7150.637-0.7850.002
PT5.3 mm70.062.10.6560.675-0.7300.058
SR1.0490.061.40.7900.718-0.852< 0.001